Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28606663 | 0.84 | MEN1 (0.45) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL20967879 | 0.80 | KMT2A (0.43) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL360667 | 0.77 | SMN1; SMN2 (0.51) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL22904500 | 0.76 | KMT2A (0.45) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL28616470 | 0.76 | KMT2A (0.47) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL22904600 | 0.75 | VEGFA (0.44) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL17999562 | 0.75 | KMT2A (0.50) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL6522396 | 0.74 | SMN1; SMN2 (0.56) | MEN1KMT2AGAASMN1; SMN2MAPT | |
| SCHEMBL1654418 | 0.74 | KDM4E (0.51) | MEN1KMT2AGAAMAPTNPSR1 | |
| SCHEMBL11371952 | 0.74 | SMN1; SMN2 (0.39) | MEN1KMT2AGAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220281831-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281831-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CDR2 | MEN1 2185/4885KMT2A 1745/4885GAA 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.